{"id":"NCT00556322","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer Who Have Experienced Disease Progression During Platinum-based Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2007-11-12","resultsPosted":"2015-02-23","lastUpdate":"2015-02-23"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Alimta or Taxotere","otherNames":[]},{"type":"DRUG","name":"erlotinib [Tarceva]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva and that of standard of care chemotherapy in patients with advanced, recurrent, or metastatic NSCLC experiencing disease progression after failure of platinum-based chemotherapy.Eligible patients will be randomized to receive either Tarceva 150mg po daily, or comparator (either Alimta 500mg/m2 every 3 weeks, or Taxotere 75mg/m2 every 3 weeks). The anticipated time on study treatment is until disease progression ,and the target sample size is 500+ individuals.","primaryOutcome":{"measure":"Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010)","timeFrame":"Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 or Death and Every 12 Weeks until Death or Data Cut off (07 September 2010) up to 52 months","effectByArm":[{"arm":"Comparator","deltaMin":81,"sd":null},{"arm":"Erlotinib","deltaMin":77.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":123,"countries":["Australia","Austria","Belgium","Canada","Chile","China","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Lithuania","Malaysia","New Zealand","Poland","Romania","Russia","Slovakia","Slovenia","South Africa","South Korea","Spain","Ukraine","United Kingdom","Venezuela"]},"refs":{"pmids":["22277837"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":213},"commonTop":["Rash","Diarrhoea","Dyspnoea","Nausea","Decreased appetite"]}}